The NATCO CL fallout
The compulsory licence granted to Natco may not be a trendsetter but it will shake up the pharmaceuticals market
A patent triumph of public interest
New flexibilities make public interest safeguards integral to drug patent rights
US keeps India out of Priority Foreign Country list of 'worst IP offenders'
US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
Indian company gets licence to manufacture and sell patented cancer drug
This is the first-ever compulsory licence given to a generic drug company